Salud financiera de hoja de balance de Biocon

Salud financiera controles de criterios 1/6

Biocon tiene un patrimonio de accionistas total de ₹242.8B y una deuda total de ₹182.5B, lo que sitúa su ratio deuda-patrimonio en 75.2%. Sus activos y pasivos totales son ₹545.8B y ₹303.0B respectivamente. El BAIT de Biocon es de ₹20.2B, por lo que su ratio de cobertura de intereses es de 2.3. Tiene efectivo e inversiones a corto plazo que ascienden a ₹37.9B.

Información clave

75.2%

Ratio deuda-patrimonio

₹182.52b

Deuda

Ratio de cobertura de intereses	2.3x
Efectivo	₹37.86b
Patrimonio	₹242.77b
Total pasivo	₹303.00b
Activos totales	₹545.77b

Actualizaciones recientes sobre salud financiera

Recent updates

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Mar 28

Biocon (NSE:BIOCON) Seems To Use Debt Quite Sensibly

Dec 27

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Nov 25

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (₹140.7B) de BIOCON superan a sus pasivos a corto plazo (₹103.7B).

Pasivo a largo plazo: Los activos a corto plazo (₹140.7B) de BIOCON no cubren sus pasivos a largo plazo (₹199.3B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de BIOCON (59.6%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de BIOCON ha crecido de 34.2% a 75.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de BIOCON no está bien cubierta por el flujo de caja operativo (6.4%).

Cobertura de intereses: Los pagos de intereses de la deuda de BIOCON no están bien cubiertos por el BAIT (2.3x cobertura).

Salud financiera de hoja de balance de Biocon

Salud financiera controles de criterios 1/6

Información clave

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Biocon (NSE:BIOCON) Seems To Use Debt Quite Sensibly

Recent updates

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Insider recently sold ₹1.1m worth of stock

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated

Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023

Insider recently sold ₹13m worth of stock

Insider recently sold ₹40m worth of stock

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Insider recently sold ₹4.2m worth of stock

Consensus forecasts updated

Biocon Limited Announces Board Changes

Second quarter 2023 earnings released: EPS: ₹0.39 (vs ₹1.16 in 2Q 2022)

Biocon Limited to Report Q2, 2023 Results on Nov 14, 2022

Insider recently sold ₹4.1m worth of stock

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Insider recently sold ₹3.8m worth of stock

Price target decreased to ₹379

Consensus EPS estimates fall by 16%

Biocon Limited Announces Directors Resignation

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocon Limited to Report Q3, 2023 Results on Jan 24, 2023

Biocon Limited to Report Q1, 2023 Results on Jul 27, 2022

Biocon Limited (NSEI:BIOCON) agreed to acquire 26% stake in AMPYR Renewable Energy Resources Eleven Private Limited for INR 75 million.

Upcoming dividend of ₹0.50 per share

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate